Skip to main content
SpringerLink
Log in

HER-2 inhibitor-related cardiovascular adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Cardiotoxicity with human epidermal growth factor receptor-2 inhibitors in breast cancer: Disproportionality analysis of the FDA adverse event reporting system International Journal of Cardiology : 9 Jan 2023. Available from: URL: https://doi.org/10.1016/j.ijcard.2022.12.043

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

HER-2 inhibitor-related cardiovascular adverse events. Reactions Weekly 1941, 10 (2023). https://doi.org/10.1007/s40278-023-32273-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-32273-9

Search

Navigation